Patterns of Mental Health Service Use and Unmet Needs for Care in Individuals with Schizophrenia
Lieberman JA, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety, and cost outcomes of CATIE and other trials, J Clin Psychiatry 2007;68:e04.
Mojtabai R, Nicholson RA, Carpenter BN, Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies,
Schizophr Bull, 1998;24:569–87.
Dickey B, Normand SL, Hermann RC, et al., Guideline recommendations for treatment of schizophrenia: the impact of managed care, Arch Gen Psychiatry, 2003;60:340–48.
Fischer EP, McCarthy JF, Ignacio RV, et al., Longitudinal patterns of health system retention among veterans with schizophrenia or bipolar disorder, Community Ment Health J, 2008;44:321–30.
Jablensky A, McGrath J, Herrman H, et al., Psychotic disorders in urban areas: an overview of the Study on Low
Prevalence Disorders, Aust N Z J Psychiatry, 2000;34:221–36.
Lehman AF, Steinwachs DM, Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey, Schizophr Bull, 1998;24:11–20, discussion 20–32.
McCarthy JF, Blow FC, Valenstein M, et al., Veterans Affairs Health System and mental health treatment retention among patients with serious mental illness: evaluating accessibility and availability barriers, Health Serv Res, 2007;42:1042–60.
Mojtabai R, Lavelle J, Gibson PJ, et al., Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996, Psychiatr Serv, 2002;53: 337–9.
Valenstein M, Blow FC, Copeland LA, et al., Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors, Schizophr Bull, 2004;30:255–64.
10. Valenstein M, Ganoczy D, McCarthy JF, et al., Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review, J Clin Psychiatry, 2006;67:1542–50.
11. Young AS, Sullivan G, Burnam MA, Brook RH, Measuring the quality of outpatient treatment for schizophrenia, Arch Gen Psychiatry, 1998;55:611–17.
12. Link BG, Dohrenwend BP, Formulation of hypotheses about the ratio of untreated to treated cases in the true prevalence studies of functional psychiatric disorders in adults in the United States. In: Dohrenwend BP (ed.), Mental
illness in the United States: Epidemiological estimates, 1980:133–49.
13. Robins LN, Regier DA, Psychiatric disorders in America: the epidemiologic catchment area study, New York: Free Press; Toronto: Collier Macmillan Canada; New York: Maxwell Macmillan International, 1991.
14. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC, Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey,
Arch Gen Psychiatry, 1996;53:1022–31.
15. Kessler RC, Zhao S, Katz SJ, et al., Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey, Am J Psychiatry, 1999;156:115–23.
16. Kessler RC, Birnbaum H, Demler O, et al., The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R), Biol Psychiatry, 2005;58:668–76.
17. Regier DA, Kaelber CT, Rae DS, et al., Limitations of diagnostic criteria and assessment instruments for mental disorders. Implications for research and policy, Arch Gen Psychiatry, 1998;55:109–15.
18. Mojtabai R, Fochtmann L, Chang SW, et al., Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study,
Schizophr Bull, 2009;35:679–95.
19. Eaton WW, Hall AL, Macdonald R, McKibben J, Case identification in psychiatric epidemiology: a review,
Int Rev Psychiatry, 2007;19:497–507.
20. Diamond PM, Wang EW, Holzer CE, 3rd, et al., The prevalence of mental illness in prison, Adm Policy Ment Health, 2001;29:21–40.
21. Teplin LA, Abram KM, McClelland GM, et al., Detecting mental disorder in juvenile detainees: who receives
services, Am J Public Health, 2005;95:1773–80.
22. Castle NG, Shea DG, Mental health services and the mortality of nursing home residents, J Aging Health, 1997;9:498–513.
23. Moak G, Borson S, Mental health services in long-term care: still an unmet need, Am J Geriatr Psychiatry, 2000;8: 96–100.
24. Jablensky A, Sartorius N, Ernberg G, et al., Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study, Psychol Med
Monogr Suppl, 1992;20:1–97.
25. Jablensky A, Epidemiology of schizophrenia: the global burden of disease and disability, Eur Arch Psychiatry Clin Neurosci, 2000;250:274–85.
26. Bromet EJ, Schwartz JE, Fennig S, et al., The epidemiology of psychosis: the Suffolk County Mental Health Project,
Schizophr Bull, 1992;18:243–55.
27. Mojtabai R, Herman D, Susser ES, et al., Service use and outcomes of first-admission patients with psychotic disorders in the Suffolk County Mental Health Project,
Am J Psychiatry, 2005;162:1291–8.
28. Lennon MC, McAllister W, Kuang L, Herman DB, Capturing intervention effects over time: reanalysis of a critical time intervention for homeless mentally ill men, Am J Public Health, 2005;95:1760–66.
29. Muthen LK, Muthen BO, Mplus User’s Guide, Los Angeles, CA: Muthen & Muthen, 1998–2007.
30. Nagin DS, Tremblay RE, Analyzing developmental trajectories of distinct but related behaviors: a group-based method, Psychol Methods, 2001;6:18–34.
31. Endicott J, Spitzer RL, Use of the Research Diagnostic Criteria and the Schedule for Affective Disorders and Schizophrenia to study affective disorders, Am J Psychiatry, 1979;136:52–6.
32. Leslie DL, Rosenheck RA, Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors,
Med Care, 2001;39:923–33.
33. Walkup JT, McAlpine DD, Olfson M, et al., Patients with schizophrenia at risk for excessive antipsychotic dosing,
J Clin Psychiatry, 2000;61:344–8.
34. West JC, Wilk JE, Olfson M, et al., Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice, Psychiatr Serv, 2005;56:283–91.
35. Goldman M, Healy DJ, Florence T, et al., Assessing conformance to medication treatment guidelines for schizophrenia in a community mental health center (CMHC),
Community Ment Health, J 2003;39:549–55.
36. Busch AB, Frank RG, Lehman AF, The effect of a managed behavioral health carve-out on quality of care for medicaid patients diagnosed as having schizophrenia, Arch Gen Psychiatry, 2004;61:442–8.
37. Frank RG, Berndt ER, Busch AB, Lehman AF, Quality- Constant ‘Prices’ for the Ongoing Treatment of Schizophrenia: An Exploratory Study*, Q Rev Econ Finance, 2004;44:390–409.
38. Mechanic D, Managing behavioral health in Medicaid,
N Engl J Med, 2003;348:1914–16.
39. Ray WA, Daugherty JR, Meador KG, Effect of a mental health ‘carve-out’ program on the continuity of antipsychotic
therapy, N Engl J Med, 2003;348:1885–94.
40. Stiles PG, Boothroyd RA, Dhont K, et al., Adherence to Practice Guidelines, Clinical Outcomes, and Costs Among Medicaid Enrollees With Severe Mental Illnesses,
Eval Health Prof, 2009;32:69–89.
41. Soumerai SB, Zhang F, Ross-Degnan D, et al., Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change, Health Aff (Millwood), 2008;27:w185–95.
42. Simoni-Wastila L, Zuckerman IH, Shaffer T, et al., Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverage, Health Serv Res, 2008;43:496–514.
43. Busch AB, Frank RG, Lehman AF, Greenfield SF, Schizophrenia, co-occurring substance use disorders and quality of care: the differential effect of a managed behavioral health care carve-out, Adm Policy Ment Health, 2006;33:388–97.
44. Wallace NT, Bloom JR, Hu TW, Libby AM, Medication treatment patterns for adults with schizophrenia in Medicaid managed care in Colorado, Psychiatr Serv, 2005;56:1402–8.
45. Chou AF, Wallace N, Bloom JR, Hu TW, Variation in outpatient mental health service utilization under capitation,
J Ment Health Policy Econ, 2005;8:3–14.
46. Bromet EJ, Hamdy A, The Suffolk County Mental Health Project: Physical health. Paper presented at: Mental Health America, 2008; Washington, DC.
47. Leucht S, Burkard T, Henderson J, et al., Physical illness and schizophrenia: a review of the literature, Acta Psychiatr Scand, 2007;116:317–33.
48. Druss BG, Bradford WD, Rosenheck RA, et al., Quality of medical care and excess mortality in older patients with mental disorders, Arch Gen Psychiatry, 2001;58:565–72.
49. Druss BG, Bradford DW, Rosenheck RA, et al., Mental disorders and use of cardiovascular procedures after myocardial infarction, JAMA, 2000;283:506–11.
50. Mitchell AJ, Malone D, Physical health and schizophrenia,
Curr Opin Psychiatry, 2006;19:432–7.
51. Saha S, Chant D, McGrath J, A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?, Arch Gen Psychiatry, 2007;64:1123–31.
52. Morrato EH, Newcomer JW, Allen RR, Valuck RJ, Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data, J Clin Psychiatry, 2008;69:316–22.
53. Young AS, Niv N, Cohen AN, et al., The Appropriateness of Routine Medication Treatment for Schizophrenia, Schizophr Bull, 2008 (Epub ahead of print).
54. Himelhoch S, Leith J, Goldberg R, et al., Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who
smoke, Gen Hosp Psychiatry, 2009;31:30–32.
55. Meyer JM, Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial,
J Clin Psychiatry, 2007;68(Suppl. 1):28–33.
56. Institute of Medicine, Improving the quality of health care for mental and substance-use conditions, Washington, DC: National
Academies Press, 2006.
57. Essock SM, Covell NH, Leckman-Westin E, et al., Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York state, Psychiatr Serv, 2009;60:1595–1602.
58. Swartz MS, Wagner HR, Swanson JW, et al., Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study, J Nerv Ment Dis, 2006;194:164–72.
59. Dixon L, Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes,
Schizophr Res, 1999;35(Suppl.):S93–100.
60. Blanchard JJ, Brown SA, Horan WP, Sherwood AR, Substance use disorders in schizophrenia: review, integration, and a proposed model, Clin Psychol Rev, 2000;20:207–34.
61. Drake RE, Green AI, Current research on co-occurring substance-use disorder in schizophrenia, Schizophr Bull, 2006;32:616–17.
62. de Leon J, Diaz FJ, A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors, Schizophr Res, 2005;76:135–57.
63. Marchibroda JM, The impact of health information technology on collaborative chronic care management,
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68